RxDoctor Payments Data

Alyssa Churchill, DO

Internal Medicine · Grand Rapids, MINPI 1699018135

Payments from drug & device makers

$2,631in general payments, 2019–2025

Across 134 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$607
  • AstraZeneca$339
  • GSK$273
  • Boehringer Ingelheim$184
  • Pfizer$127
  • Antares Pharma, Inc.$118
  • plus $982 from 21 others

What the payments were for

  • Food & beverage$2,631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,631 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$13,240
Medicare patients
46
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$22,713
Estradiol20$1,438
PaxlovidNirmatrelvir/Ritonavir11$1,429
Venlafaxine Hcl ErVenlafaxine Hcl14$1,084
Atorvastatin Calcium58$823
Rosuvastatin Calcium51$794
Omeprazole29$734
Bupropion XlBupropion Hcl15$667
Celecoxib17$646
Levothyroxine Sodium37$641
Pregabalin13$605
Losartan Potassium32$588
Gabapentin11$388
Carvedilol23$374
Escitalopram Oxalate28$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$607$22,71321 claims
PfizerPaxlovid$127$1,42911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →